Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cantex Pharmaceuticals, Inc.

http://www.cantex.com/

Latest From Cantex Pharmaceuticals, Inc.

Deal Watch: Aevi Options AstraZeneca Antibody For Rare Disease

Aevi needs to raise funds first, but hopes to develop MEDI2338 for adult-onset Still’s disease. Also, Alnylam plans to leverage Ironwood’s GI expertise for givosiran in acute hepatic porphyria and Ultragenyx snags option to buy GeneTx.

Deals M & A

Start-Up Previews (6/05)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, New Drugs for Myocardial Infarction, features profiles of ArgiNOx Pharmaceuticals, ParinGenix and VasoGenix Pharmaceuticals. Plus these Start-Ups Across Health Care: AngioScore, Hamilton Pharmaceuticals, Ikaria, Light BioScience and Potentia Pharmaceuticals.

ParinGenix Inc.

ParinGenix Inc. is currently developing a modified form of the widely used anticoagulant, heparin, to treat cardiac ischemia-reperfusion injury following myocardial infarction.

BioPharmaceutical Research and Development Strategies

New Drugs for Myocardial Infarction

Ischemia-induced damage isn't the only harmful effect of heart attacks, and a number of recently founded companies are investigating new mechanisms to protect the heart.

BioPharmaceutical Research and Development Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Biotechnology
    • Synthesis Technologies, Production Processes
UsernamePublicRestriction

Register